Performance data help justify breast MRI’s whopping price tag for high-risk screening

November 28, 2007

MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the U.S. if new American Cancer Society guidelines are followed.

MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the U.S. if new American Cancer Society guidelines are followed.A large prospective study from the University of Pennsylvania compared screen-film mammography, digital mammography, whole-breast ultrasound, and contrast-enhanced MRI in a screening population of 569 asymptomatic women. All participants had had a negative mammogram and negative physical exam.

High-risk was defined as including the following risk factors:

  • a 25% lifetime risk based on genetic testing, Gail or Claus models
  • diagnosis of lobular carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia
  • exposure to radiation prior to puberty
  • history of cancer in the contralateral breast

Three radiologists made the interpretations in a blinded fashion, and the results were later unblinded at conference. One physician read the screen-film and whole-breast ultrasound studies, the second interpreted digital mammography, and the third performed the CE-MRI readings.

Of 95 lesions recommended for biopsy, 11 were malignant (11.6%). Half of these were invasive ductal carcinoma, and the remaining half included invasive lobular carcinoma, invasive cancer not otherwise specified, and ductal carcinoma in situ.

Of these 11 cancers, the various modalities detected:

  • screen-film mammography, two of 11
  • digital mammography, four of 11
  • MRI, 10 of 11
  • whole-breast ultrasound, two of 11

Seven of the 11 cancers were seen on only one modality: one with digital mammography and six with MRI alone. No cases were seen on either screen-film mammography or ultrasound alone.

"In our study, MRI detected the highest percentage of clinically occult breast cancers in a high-risk population, more than digital mammography, ultrasound, and screen-film mammography. Breast MRI may be a useful screening tool in addition to mammography in the high-risk population," said presenter Dr. Lily Kernagis, a fellow in women's imaging at Penn.Follow-up was carried out for one to three years and revealed no new breast cancer diagnoses. Based on the results and follow-up, multimodality screening had a negative predictive value of 100%, sensitivity of 100%, and specificity of 84.9%.In March of this year, the American Cancer Society recommended that high-risk women have breast MRI along with mammography in annual screening.

The guidelines apply to women with:

  • lifetime risk of breast cancer of 20% or greater
  • exposure to radiation of the chest between the ages of 10 and 30
  • Li Fraumeni syndrome, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, or possibility of having one of these syndromes based on history in first-degree relative

Another study presented during the same session found that 1.8 million women are at high risk according to the ACS definition, and they should be getting supplemental breast MRI. The majority of these women -- 1.7 million -- qualify on the basis of a strong family history, said Dr. Rand Stack, section chief of the Breast Imaging Center at White Plains Hospital in New York.

Assuming average charges of $1038 for initial MRI with 100% screening compliance, direct costs for adding MRI as a supplemental screening tool would amount to about $1.9 billion a year. If compliance was more along the lines of mammography screening guidelines, with 75% of women participating, direct costs would reach $1.4 billion a year. Use of breast MRI would also create indirect costs related to follow-up studies (average price $793) and biopsies. Researchers estimated indirect costs would add another $573 million in annual expenses, assuming 100% compliance with the screening guidelines and not including other indirect costs such as lost days of work resulting from MRI appointments or biopsies. Currently, 28 million MRI exams for all organs are performed in the U.S. annually, so adding 1.8 million studies would equate to a 6% increase in the MRI study volume, said Stack, who is also vice president of the New York Breast Imaging Society. Industry sources suggest there is sufficient excess capacity in the installed MR scanner base to absorb a 6% increase, though it is unclear how many machines are equipped with breast coils, he said.Assuming the 14,000 physicians currently performing mammography all performed breast MRI, the workforce also seems to have the capacity needed to manage breast MRI. Workload would increase by two or three breast MRI interpretations per week, Stack said. A recent

survey

of breast imaging specialists showed 75% were performing breast MRI, albeit at a low volume. But recent figures for the number of physicians performing mammography more generally are not available. Attendees and panelists at the RSNA session said it seems unlikely that all radiologists currently performing mammography would also offer breast MRI.